Medicus Pharma Analyst Ratings
Medicus Pharma Ltd's Promising Clinical Developments and Strategic Expansion Drive Buy Rating
Medicus Pharma Is Maintained at Buy by D. Boral Capital
Medicus Pharma Analyst Ratings
D. Boral Capital Initiates Coverage On Medicus Pharma With Buy Rating, Announces Price Target of $14
Medicus Pharma Ltd: Promising Phase 2 Results and Market Potential Drive Buy Rating
Maxim Group Maintains Medicus Pharma(MDCX.US) With Buy Rating, Maintains Target Price $10
Medicus Pharma Ltd Poised for Growth: Buy Rating Reaffirmed Amid Promising Developments and Upcoming Catalysts
Maxim Group Initiates Medicus Pharma(MDCX.US) With Buy Rating, Announces Target Price $10
Medicus Pharma Ltd: Innovative D-MNA Product Positions Company for Success With Favorable Buy Rating
Brookline Capital Initiates Medicus Pharma(MDCX.US) With Buy Rating, Announces Target Price $12
Medicus Pharma Initiated With a Buy at Brookline
Medicus Pharma Analyst Ratings
Maxim Group Initiates Coverage On Medicus Pharma With Buy Rating, Announces Price Target of $10
Maxim Group Initiates Medicus Pharma(MDCX.US) With Buy Rating, Announces Target Price $10